Interestingly, in cancers like ovarian, breast, pancreatic, head and neck, lung, biliary tract, colorectal, stomach, endometrial, kidney, and sarcoma, patients with only TP53 biallelic alterations had higher HRD scores than those with only HRR biallelic alterations, highlighting TP53’s strong influence on HRD. This evidence concerns the gene TP53 and cancer.